Dysregulation of receptor tyrosine kinase (RTK) signaling leads to lung cancer, such as activating EGFR mutations are present in 15% of NSCLC, BRAF and KRAS always also mutated in lung cancer [13, 14]. This evidence concerns the gene KRAS and lung cancer.